Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 58Squamous Cell Carcinoma of Head and Neck 37Nasopharyngeal Carcinoma 27Lung Neoplasms 25Uterine Cervical Neoplasms 22Biliary Tract Neoplasms 22Esophageal Squamous Cell Carcinoma 20Oropharyngeal Neoplasms 18Head and Neck Neoplasms 17Cholangiocarcinoma 16Urinary Bladder Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Ovarian Neoplasms 13Esophageal Neoplasms 12Carcinoma 12Colorectal Neoplasms 11Stomach Neoplasms 10Small Cell Lung Carcinoma 10Carcinoma, Transitional Cell 8Mouth Neoplasms 7Laryngeal Neoplasms 7Hypopharyngeal Neoplasms 7Carcinoma, Squamous Cell 7Recurrence 6Nasopharyngeal Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Bile Duct Neoplasms 5Peritoneal Neoplasms 4

Interventions

Carboplatin 4pertuzumab 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Paclitaxel 2Oxaliplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1talazoparib 1sarilumab 1relugolix 1regorafenib 1pexidartinib 1pembrolizumab 1patritumab 1olaparib 1niraparib 1nimotuzumab 1neratinib 1ganitumab 1enzalutamide 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pathologic Complete Response × Cisplatin × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡